Advanced search
1 file | 637.77 KB Add to list

Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma

Author
Organization
Keywords
Cancer Research, Oncology, Radiation, Radiology Nuclear Medicine and imaging, SOLID TUMORS, RADIOTHERAPY, IPILIMUMAB, PEMBROLIZUMAB, COMBINATION, GUIDELINES, ANTI-PD-1, SURVIVAL, IMMUNITY, CANCER

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 637.77 KB

Citation

Please use this url to cite or link to this publication:

MLA
Sundahl, Nora, et al. “Phase 2 Trial of Nivolumab Combined with Stereotactic Body Radiation Therapy in Patients with Metastatic or Locally Advanced Inoperable Melanoma.” INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 104, no. 4, 2019, pp. 828–35, doi:10.1016/j.ijrobp.2019.03.041.
APA
Sundahl, N., Seremet, T., Van Dorpe, J., Neyns, B., Ferdinande, L., Meireson, A., … Ost, P. (2019). Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 104(4), 828–835. https://doi.org/10.1016/j.ijrobp.2019.03.041
Chicago author-date
Sundahl, Nora, Teofila Seremet, Jo Van Dorpe, Bart Neyns, Liesbeth Ferdinande, Annabel Meireson, Lieve Brochez, Vibeke Kruse, and Piet Ost. 2019. “Phase 2 Trial of Nivolumab Combined with Stereotactic Body Radiation Therapy in Patients with Metastatic or Locally Advanced Inoperable Melanoma.” INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 104 (4): 828–35. https://doi.org/10.1016/j.ijrobp.2019.03.041.
Chicago author-date (all authors)
Sundahl, Nora, Teofila Seremet, Jo Van Dorpe, Bart Neyns, Liesbeth Ferdinande, Annabel Meireson, Lieve Brochez, Vibeke Kruse, and Piet Ost. 2019. “Phase 2 Trial of Nivolumab Combined with Stereotactic Body Radiation Therapy in Patients with Metastatic or Locally Advanced Inoperable Melanoma.” INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 104 (4): 828–835. doi:10.1016/j.ijrobp.2019.03.041.
Vancouver
1.
Sundahl N, Seremet T, Van Dorpe J, Neyns B, Ferdinande L, Meireson A, et al. Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2019;104(4):828–35.
IEEE
[1]
N. Sundahl et al., “Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma,” INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 104, no. 4, pp. 828–835, 2019.
@article{8667707,
  author       = {Sundahl, Nora and Seremet, Teofila and Van Dorpe, Jo and Neyns, Bart and Ferdinande, Liesbeth and Meireson, Annabel and Brochez, Lieve and Kruse, Vibeke and Ost, Piet},
  issn         = {0360-3016},
  journal      = {INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS},
  keywords     = {Cancer Research,Oncology,Radiation,Radiology Nuclear Medicine and imaging,SOLID TUMORS,RADIOTHERAPY,IPILIMUMAB,PEMBROLIZUMAB,COMBINATION,GUIDELINES,ANTI-PD-1,SURVIVAL,IMMUNITY,CANCER},
  language     = {eng},
  number       = {4},
  pages        = {828--835},
  title        = {Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma},
  url          = {http://dx.doi.org/10.1016/j.ijrobp.2019.03.041},
  volume       = {104},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: